Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957431 · ClinicalTrials.gov registry record · Phase 1
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
A Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06957431: Recruiting Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma, sponsored by Washington University School of Medicine.
NCT06957431 is a Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06957431, a Phase 1 study of Advanced Leiomyosarcoma and Adipocytic Sarcoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Primary Outcome
Graded using CTCAE version 5.0.
Conditions Studied
Interventions
- DRUG Zanzalintinib
- DRUG Eribulin
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2033-10-31 |
| Phase | Phase 1 |
What NCT06957431 shows while recruiting
NCT06957431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Advanced Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Zanzalintinib is the first listed.
NCT06957431 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06957431 about?
NCT06957431 is a clinical study titled "Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma". The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
What is the current status of trial NCT06957431?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-10-22. Estimated completion is 2033-10-31.
What conditions does trial NCT06957431 study?
This clinical trial studies the following conditions: Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma.
What interventions are being tested in trial NCT06957431?
The interventions under investigation include: Zanzalintinib (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT06957431?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06957431 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06957431's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI